Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Prothena Corporation plc (PRTA)

56.71   -4.5 (-7.35%) 11-28 16:00
Open: 60.11 Pre. Close: 61.21
High: 62 Low: 56.52
Volume: 393,347 Market Cap: 2,743(M)

Technical analysis

as of: 2022-11-28 4:42:28 PM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 70.35     One year: 76.32
Support: Support1: 51.95    Support2: 43.23
Resistance: Resistance1: 60.23    Resistance2: 65.34
Pivot: 58.33
Moving Average: MA(5): 60.15     MA(20): 58.6
MA(100): 42.29     MA(250): 37.43
MACD: MACD(12,26): 1.4     Signal(9): 1.7
Stochastic oscillator: %K(14,3): 66.1     %D(3): 71.9
RSI: RSI(14): 48.4
52-week: High: 65.34  Low: 21.05
Average Vol(K): 3-Month: 845 (K)  10-Days: 483 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PRTA ] has closed above bottom band by 35.1%. Bollinger Bands are 14.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 62.06 - 62.4 62.4 - 62.68
Low: 55.75 - 56.15 56.15 - 56.47
Close: 56.11 - 56.72 56.72 - 57.22

Company Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Headline News

Fri, 25 Nov 2022
Should You Add Prothena Corporation PLC (PRTA) Stock to Your Portfolio Friday? - InvestorsObserver

Mon, 21 Nov 2022
2022-11-21 | NDAQ:PRTA | Press Release | Prothena Corporation plc - Stockhouse

Fri, 18 Nov 2022
Free and fun things to do on the Point - All Point Bulletin

Fri, 18 Nov 2022
Prothena Co. plc (NASDAQ:PRTA) CAO Karin L. Walker Sells 10000 Shares - MarketBeat

Mon, 14 Nov 2022
Should You Accumulate Prothena Corporation PLC (PRTA) Stock Monday Morning? - InvestorsObserver

Wed, 09 Nov 2022
Insider Selling: Prothena Co. plc (NASDAQ:PRTA) Director Sells 5000 Shares of Stock - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 48 (M)
% Held by Insiders 2.266e+007 (%)
% Held by Institutions 5.2 (%)
Shares Short 3,260 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.6379e+008
EPS Est Next Qtl -1.56
EPS Est This Year -4.41
EPS Est Next Year -5.37
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 193.1
Return on Equity (ttm) -17.4
Qtrly Rev. Growth 5.15e+006
Gross Profit (p.s.) -206.05
Sales Per Share -72.84
EBITDA (p.s.) 2.46438e+008
Qtrly Earnings Growth 1.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -126 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 32
Price to Book value 0
Price to Sales -0.78
Price to Cash Flow 3.22

Stock Dividends

Dividend 0
Forward Dividend 2.43e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.